派格生物医药-B今日盘中大涨5.02%，股价表现强劲。
消息面上，此次上涨主要得益于公司核心产品商业化取得重大进展。派格生物此前已与腾瑞制药就其核心产品派达康（维培那肽注射液）签署了在中国大陆的独家商业化战略合作协议，双方确立了累计销售规模超100亿元人民币的核心目标，腾瑞制药将为此支付约1.4亿港元的权益金。此外，腾瑞制药还与方舟健客签署战略合作，派达康将在其互联网医院平台进行全网首发，这进一步拓宽了产品的市场渠道，增强了市场对公司GLP-1类药物未来销售前景的乐观预期。
派格生物医药是一家专注于慢性病创新疗法的生物制药公司，其核心产品PB-119（即派达康）是国内最早研发的长效GLP-1受体激动剂之一，主要应用于2型糖尿病、肥胖症等代谢疾病领域。此次商业化合作的落地，被视为公司价值兑现的关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.